Sherene Loi MD

The chemo-free combo of Ribo+Let+trastuzumab led to mOFS 30.4 months, good ORR, and minimal cardiac toxicity in this ph2 1L Korean study. #ASCO25 @oncoalert.bsky.social

Pleased to be part of these elections!

In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups.

Full article in the #ESMODailyReporter

🔗 ow.ly/rtbo50VSyiN

DIAmOND Trial at ESMO Breast 2025 Shows Activity of Durvalumab and Tremelimumab in Trastuzumab-Resistant HER2 Positive Breast Cancer - OncoDaily Dual checkpoint blockade with tremelimumab + durvalumab shows promise in HER2-positive advanced breast cancer with trastuzumab resistance in the DIAmOND trial at ESMO 2025.

DIAmOND Trial at ESMO Breast 2025 Shows Activity of Durvalumab and Tremelimumab in Trastuzumab-Resistant HER2+ Breast Cancer
@myesmo.bsky.social @loisher.bsky.social

oncodaily.com/science/diam...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DIAmOND #ESMOBreast25

🎈🎈🎈news day for #HER2 pos #breastcancer. Will look fwd to seeing the HR and comparable toxicity profiles
www.astrazeneca.com/media-centre...

Triple-Negative Breast Cancer: Neoadjuvant Nivolumab Initiation The phase II Neo-N trial investigated the activity of two differing schedules of neoadjuvant nivolumab initiation—lead-in or concurrent—with 12 weeks of carboplatin and paclitaxel in patients with ear...

Does the timing of neoadjuvant nivolumab initiation affect outcomes in early-stage triple-negative breast cancer?
A phase II study led by Dr. Sherene Loi explores this critical question.
Read more: ascopost.com/news/march-2...
#TripleNegativeBreastCancer #Immunotherapy

Dr. Janni reviews ongoing ctDNA trials w/de-escalation, escalation. Starts with historical perspective that attempts to use CT/body imaging for early disease recurrence did NOT improve overall survival, only increased detection of recurrence (lead time bias). #SGBCC2025

@thelancet.bsky.social the Lancet summit for cancer control in China 🇨🇳
Great discussion for #breastcancer #lungcancer #GIcancers

Many good things to say on this story @oncoalert.bsky.social @naturemedicine.bsky.social: 1) serious biomarker work from a pharma-sponsored trial👏👏 2) a tumor historically consid cold 🥶can respond to aPD1 🤩3) we need to redefine ER+ disease to enable personalized treatm✍️

Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials | JCO P... PURPOSETo investigate whether hormone receptor–positive, human epidermal growth factor receptor 2–low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characte...

🚩pleased to share our latest "Genomic Characterisation and Prognostic Significance of HER2–Low, HR+, Early #Breastcancer From the BIG 1-98 and SOFT Clinical Trials" #bcsm using centrally reviewed HER2 IHC from 2 large clinical trials #IBCSG @oncoalert.bsky.social 👏
ascopubs.org/doi/10.1200/...

🎈our recent collaborative review on “Complexities of Cancer” highlighted here 👏👏👏 🙏 @cp-cell.bsky.social as well as many other seminal articles- well worth a look 👀 @oncoalert.bsky.social

Remembering Jose Baselga and the superstar 👏⭐️ he was

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial Nature Medicine - In the CheckMate 7FL trial, neoadjuvant nivolumab and chemotherapy in patients with newly diagnosed, high-risk estrogen receptor-positive breast cancer led to an increased...

summary CM-7FL @oncoalert.bsky.social
@naturemedicine.bsky.social link: rdcu.be/d8Cw4.
Here Nivo ⬆️ pCR rates in high grade HR+ BC. Increasing pCR rates in this subtype is HARD! PD-L1+ & #TIL higher pCR. This study will change how we think about HR+BC- some are immunogenic & need PD-1i with chemo

🎈Adjuvant Atezo for fully resected #TNBC #breastcancer is of NO benefit. We’ll see soon results from SWOG trial in re post neoadjuvant (w/o IO). Exposure to antigen and draining LN seems v. important for ICB efficacy. @oncoalert.bsky.social #bcsm

➡️➡️ very exciting news for estrogen receptor + #breastcancer- a subset is very immunogenic - this data changes the way we think about T cell immunosurveillance in this BC subtype
👏👏👏

Next time I’d love to be there!

📌 Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
👉🏻 sciencedirect.com/science/articl…
@ilanaschlam.bsky.social @loisher.bsky.social
@oncoalert.bsky.social

Looking fwd to the joint annual meeting of 🇯🇵 #jcog #kbcs 🇰🇷#tibcs 🇹🇼 and @BCTrialsANZ 🇦🇺 in #nagoya #breastcancer trials

Great fun discussing #breastcsncer #immunotherapy in #japan #nagoya 🙏

We are incredibly proud to announce that five Peter Mac researchers have been named in Clarivate's top 1% most cited researchers worldwide for 2024.

Read more: www.petermac.org/about-us/new...

Towards targeting the breast cancer immune microenvironment Nature Reviews Cancer - In this Review, Harris et al. summarize the dynamic changes of the immune breast tumour microenvironment (TME) that take place during disease progression and in response to...

HNY everyone! Our latest review @natrevcancer.bsky.social on the #breastcancer immune microenvironment is pinned here. Looking fwd to a very exciting 2025.
rdcu.be/d51vW

#sabcs24
HR+HER2+ #breastcancer now finally its own entity 👏👏👏

#sabcs24
State of the Art session speakers Immune bio markers #til thanks to @balkolab @psharmab